Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up

This publication has 20 references indexed in Scilit:

• De novo mTOR inhibitor‐based immunosuppression in ABO‐incompatible kidney transplantation
  Clinical Transplantation, 2015
• Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
  American Journal of Transplantation, 2014
• Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
  Bone Marrow Transplantation, 2012
• Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience
  Nephrology Dialysis Transplantation, 2011
• Solid Organ Allograft Survival Improvement in the United States: The Long-Term Does Not Mirror the Dramatic Short-Term Success
  American Journal of Transplantation, 2011
• Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal
  American Journal of Transplantation, 2011
• Everolimus Plus Reduced‐Exposure CsA versus Mycophenolic Acid Plus Standard‐Exposure CsA in Renal‐Transplant Recipients
  American Journal of Transplantation, 2010
• Revised Equations for Estimated GFR From Serum Creatinine in Japan
  American Journal of Kidney Diseases, 2009
• Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients
  American Journal of Transplantation, 2005
• Chronic Renal Failure after Transplantation of a Nonrenal Organ
  New England Journal of Medicine, 2003